Cleanspace Holdings Ltd (csx) Logo

Cleanspace Holdings Ltd (CSX)

___:___ · Healthcare
0.00
0.00
(0.00)
VOLUME
DIV YIELD
PE RATIO
1 YR RETURN
52 WEEK RANGE

CSX Chart

Snapshot

CSX's Principal Activity is the the design, manufacture and sale of respirators and related products and services.

Share Price Activity

Last (Price)
Change 0.00 (0.00)
Bid / Ask -
Volume
Volume (4w avg)
Turnover
Open
Day Range -
VWAP
Prev Close
Last Trade

Performance

1 Week
1 Month
2022 YTD
1 Year
vs Sector (1yr) -34.53%
vs ASX 200 (1yr) -38.62%

Size

Market Cap Question Mark Icon
Excludes mandatory escrowed shares and foreign shares.
ASX Rank 1,090 of 2,411
Sector Rank 82 of 210

Key Fundamentals

Shares Issued
Sector Healthcare
Similar Companies MDR / MX1 / BMT
EPS -$0.089
DPS $0.00
Book Value Per Share $0.53

Broker Consensus

CSX is not covered by a major broker, or data from most recent compilation was omitted due to not meeting QA guidelines.

Announcements

Date Heading Pages File Size Time

Corporate Overview

CleanSpace Holdings Limited (CSX) is into design, manufacture and sale of respirators and related products and services and it deliver all the protection of a Powered Air Purifying Respirator are comfortable to wear and easy to use.

Incorporation Details

No incorporation details available.

Corporate Details

Head Office St Leonards NSW 2065
Website www.cleanspacetechnology.com
Registry BoardRoom
Auditor PKF
Date Listed 23 Oct 2020

Upcoming Calendar (Forecasted)

Date Event
26/08/2022 Report (Prelim)
28/10/2022 Report (Annual)
24/02/2023 Report (Interim)

Dividend History

DPS and Yield calculations use the Pay Date.

Ex-Date Amount Franking Gross Type Payable
No dividends paid.

See Upcoming Dividends for all ASX companies.

Directors & Management

Directors & Management

Name Title Since Bio
Mr Graham McLean Non-Executive Director Feb 2022

Mr Graham McLean

Non-Executive Director

Mr McLean has both the financial and commercial experience in the medical technology sector. Mr McLean has worked with NYSE-listed Stryker for 16-years and has medical device and healthcare experience. At Stryker, Mr McLean held several senior positions, including President Japan, President Australia/New Zealand and President Asia Pacific, based in Singapore and Hong Kong. During this time, Mr McLean was responsible for transforming Asia Pacific, including restructuring their China distribution. Prior to Stryker, Mr McLean held senior finance and operational roles in Asia and Europe, including international consumer brands Lion Nathan, Smiths Snackfoods (Pepsi), McVities (United Biscuits), United Distillers (Guinness) and Unilever. He is currently an advisor to Bain & Company and GLG, and a board member of Suicide Prevention Australia. Graham also has an understanding of North America and UK listed entities having worked in finance and operations roles for international companies.

Ms Lisa Ray Hennessy Non-Executive Director Dec 2021

Ms Lisa Ray Hennessy

Non-Executive Director

Ms Hennessy brings North American enterprise sales networks in the medical device and healthcare sectors, from her time with global medical technology company GE Healthcare (NYSE). Ms Hennessy also has acquisition and growth strategy experience, from in-house strategy director roles with NYSE-listed Del Monte Foods and GE Capital. Ms Hennessy's Non-Executive Board experience includes listed, private and not-for-profit organisations. She is currently serving as a Non-Executive Director with Nitro Software (ASX: NTO) and was previously a NonExecutive Director with Murray River Organics (ASX: MRG).

Mr Bruce Rathie Non-Executive Director,Non-Executive Chairman Oct 2021

Mr Bruce Rathie

Non-Executive Director,Non-Executive Chairman

Mr Rathie has more than 20 years of governance experience across a range of industries and businesses, including financial services, technology and biotechnology. Mr Rathie is currently Chair of 4DMedical Limited (ASX: 4DX) and Non-Executive Director of Cettire Limited (ASX: CTT) and PolyNovo Limited (ASX: PNV). He also has experience in law and investment banking.

Ms Elizabeth Harvey Chief Financial Officer,Joint Company Secretary Nov 2020
Ms Elissa Hansen Joint Company Secretary Nov 2020
Dr Alexandra Margaret Birrell Chief Executive Officer,Executive Director Aug 2015

Dr Alexandra Margaret Birrell

Chief Executive Officer,Executive Director

Dr Birrell has worked in senior management roles in the healthcare and technology sector for over 20 years. Her previous roles include PricewaterhouseCoopers where she worked in the healthcare advisory practice and financial services (Technology); and Royal Prince Alfred Hospital. Dr Birrell was a member of the Board of Trustees of Museum of Applied Arts & Sciences, NSW from 2016 - 2019. Dr Birrell is a previous winner of AFR Women of Influence Awards, Chief Executive Women Scholarship.

Mr Dan Kao Director-Operations & Founder,Executive Director Apr 2011

Mr Dan Kao

Director-Operations & Founder,Executive Director

Mr Kao worked in the medical and healthcare industry for over 20 years, and has experience in manufacturing, supply chain optimisation, quality management systems and in securing patents for innovative technologies in healthcare. Mr Kao is a former senior designer for ResMed Inc (Australia) (ASX:RMD). Mr Kao is a previous winner of the Australian Design Award.

Director Transactions

CSX directors must report any change in shareholding to the ASX within 5 business days.

See Director Transactions for all ASX companies.

Date Director Type Amount Price Value Notes
10/12/21 Bruce Rathie Issued 600,000 $0.265 $159,000 Issue of options
15/04/21 Ronald (Ron) Weinberger Buy +24,200 $2.061 $49,869 On-market trade

Director Interests

The current holdings of CSX directors.

Director Last Notice Direct Shares Indirect Shares Options Convertibles
Graham McLean 01/02/2022 0 N/A N/A N/A
Bruce Rathie 10/12/2021 0 N/A 600,000 N/A
Lisa Hennessy 09/12/2021 0 N/A N/A N/A
Alexandra Birrell 10/08/2015 N/A 2,798,962 220,470 N/A
Dan Kao 01/04/2011 2,530,000 N/A 68,418 N/A

Shareholder Info

Top 20 Shareholders

Data supplied by Morningstar and accurate on Oct 8, 2021.

It's not possible to publish a real-time Top 20 Shareholder list. Companies are not obliged to report this data (with the exception of Substantial Shareholders above 5%). If a company chooses to publish the data, it's usually once a year in their Annual Report.

All data is manually compiled so there might be a delay between the Annual Report being published and the data appearing on Market Index (<7 days for ASX 300 and up to 30 days for micro-caps).

Name Shares Capital
E&P Investments Limited (Cvc Investee A/C) 9,257,535 12.02%
National Nominees Limited 5,321,714 6.91%
Chatswood Wealth Management Pty Ltd 3,850,000 5.00%
BNP Paribas Noms Pty Ltd (DRP) 3,702,146 4.81%
Alex Birrell (Baf A/C) 2,798,962 3.63%
Dan Kao 2,530,000 3.29%
Elsie Flood Foundation Pty Ltd (Elsie Flood Foundation A/C) 2,398,629 3.11%
HSBC Custody Nominees (Australia) Limited 2,323,380 3.02%
Min Fang 2,057,248 2.67%
Paftec Investment Fund Pty Ltd (Paftec Unit A/C) 1,878,497 2.44%
Acorn Capital Private Opportunities Fund L P 1,670,391 2.17%
Alfred H H Myers (Lucy'S A/C) 1,449,481 1.88%
UBS Nominees Pty Ltd 1,300,300 1.69%
J P Morgan Nominees Australia Pty Limited 1,293,212 1.68%
Miss Linda Ying Wang (Kao And Wang Family A/C) 1,202,816 1.56%
Craig Lawn & Joy Lawn (Lawn Family Super Fund A/C) 1,001,871 1.30%
Peter Anthony Vogliotti 1,000,000 1.30%
Ching Ming Liu 843,406 1.10%
Lily Li-Ting Hong 836,790 1.09%
Jenny Hsu 815,734 1.06%

Shareholder Distribution

As reported in the most recent Annual Report.

Holding Size 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001+ Total
No. of Shareholders 2,151 1,399 316 265 72 4,203

Substantial Shareholders

A substantial shareholder is a person or entity that owns 5% or more of the voting shares in a company. Shares can be held through multiple entities, so the Substantial Shareholders list differs from the Top 20 Shareholders list.

Shareholding changes less than 1% do not require notification to the market. When all “Last Notice” dates are identical, it suggests that no (or minimal) change has occurred since the most recent Annual Report.

Name Last Notice Total Shares Shares Held (%)
Walsh and Company Investments Limited 08/10/2021 10,007,535 12.99
Acorn Capital Limited 08/10/2021 6,080,863 7.90
National Nominees Ltd 08/10/2021 4,342,070 5.64
One Fund Services Ltd 19/01/2022 9,257,535 12.02

Shareholders Buying

12 month transaction history compiled from ASX announcements.

Date Name Bought Previous % New %
19-01-22 One Fund Services Ltd 9,257,535 -- 12.02

Shareholders Selling

12 month transaction history compiled from ASX announcements.

No sell transactions reported by Substantial Shareholders in the past 12 months.

Historical Data

Share Price History

Date Close Change %Chg Open High Low Volume Turnover

Historical Data

Year Closing Price Last Trade
2021 $1.50 30 June
CSX Historical Price Data (CSV)
Up to 20 years of EOD share price history
You must be logged in to access this feature. Please sign up for free or login.
Market Index, ASX and Morningstar Logos

All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.